Written by Anne Schulze
When global supply chains crumbled during COVID-19, one procurement executive at Reckitt saw beyond the chaos. Through strategic multi-sourcing initiatives, Michal Cukier’s team slashed the company’s single-supplier exposure from 94% to 41%, changing how the healthcare giant sources vital ingredients.
Breaking the Single-Source Chain
The sourcing upgrade began with Airborne, Reckitt’s immune support powerhouse. As pandemic panic buying stripped store shelves bare, Cukier’s team raced to secure alternative suppliers for Vitamin C, a key ingredient.
“Traditional sole-source relationships simply weren’t sustainable anymore,” Cukier notes. “We had to take a deep, long look at how we thought about supplier relationships.“
His team engineered a network of backup suppliers across different regions. This, in turn, created redundancy that was a saving grace when primary sources faltered. A multi-source strategy, this became the blueprint for protecting Reckitt’s entire healthcare portfolio.
Even beyond regional diversification, Cukier led a novel supplier qualification process that reduced onboarding time by 60%. This acceleration proved essential when established supply lines buckled under pandemic pressures. The streamlined process allowed Reckitt to validate new partners while quickly maintaining rigorous quality standards.
Protecting an $850M Healthcare Pipeline
The next step was even more tenacious–safeguarding Reckitt’s massive portfolio of over-the-counter medicines and supplements. Cukier deployed a highly complex vulnerability assessment tool that changed how the company predicted and responded to supply disruptions.
The system’s effects were immediate and vastly-reaching. Reckitt identified major weak points in the supply chain before they broke, maintaining steady production even as competitors struggled with stockouts.
“We moved from reactive firefighting to proactive risk management,” Cukier explains. “It changed everything about how we operate, if I may boast.“
Securing America’s Medicine Cabinet
Perhaps most importantly, Cukier’s team changed the supply chain for Mucinex, Reckitt’s flagship cold and flu medicine. It established dual sourcing for active ingredients, excipients, and packaging–a strategic action that proved prescient when COVID-19 hit.
While other manufacturers faced devastating shortages, Reckitt kept Mucinex flowing to American pharmacies without interruption. The company recently doubled down on this strategy, investing $200 million in a new North Carolina manufacturing facility to strengthen its U.S. supply chain further.
Beyond one company’s bottom line, these concepts extended to securing the supply of critical healthcare products during a global crisis. Cukier’s strategies helped protect public health across North America. His multi-sourcing playbook has become a model for the industry, showing how strategic supplier diversity can build genuine supply chain resilience.
“The pandemic exposed fatal flaws in traditional sourcing models,” Cukier reflects. “But it also showed us a better way forward. The future needs more companies brave enough to try strategic redundancy, even if it means sacrificing short-term efficiency for long-term stability.“
Major pharmaceutical companies now adopt similar multi-sourcing strategies, recognizing that the old model of cost-driven single-sourcing carries unacceptable risks in a highly volatile world. The methods that began in one company’s response to the crisis have sparked a significant pivot in how the industry’s professionals think about supply chain security.
